300683.SZ
海特生物
SZSE · Healthcare · C 制造业 · CN
CNY 25.78
−11.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 543.8M | 541.4M | 649.0M | 602.3M | 688.6M |
| Cost of Revenue | 321.3M | 310.6M | 370.9M | 345.1M | 354.9M |
| Gross Profit | 222.5M | 230.9M | 278.1M | 257.2M | 333.7M |
| Operating Expenses | |||||
| R&D Expense | 80.7M | 88.2M | 121.7M | 128.9M | 121.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 117.1M | 115.1M | 119.3M | 113.3M | 93.8M |
| Selling & Marketing Expense | 155.9M | 156.1M | 126.6M | 128.7M | 126.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 357.5M | 362.9M | 369.6M | 369.2M | 336.3M |
| Cost and Expenses | 678.8M | 673.4M | 740.5M | 714.3M | 691.2M |
| Operating Income (EBIT) | (245.4M) | (234.1M) | (75.7M) | (143.1M) | (6.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (249.8M) | (238.8M) | (80.1M) | (152.0M) | (7.8M) |
| Income Tax Expense | (4.8M) | (3.3M) | (6.4M) | (23.7M) | 74.2K |
| Bottom Line | |||||
| Net Income | (240.4M) | (231.3M) | (69.3M) | (120.8M) | (14.0M) |
| Earnings from Cont. Ops | (244.9M) | (235.4M) | (73.8M) | (128.2M) | (7.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (240.4M) | (231.3M) | (69.3M) | (120.8M) | (14.0M) |
| Per Share | |||||
| Basic EPS | (CN¥1.84) | (CN¥1.77) | (CN¥0.53) | (CN¥0.93) | (CN¥0.11) |
| Diluted EPS | (CN¥1.84) | (CN¥1.77) | (CN¥0.53) | (CN¥0.93) | (CN¥0.11) |
| Revenue Per Share | CN¥4.25 | CN¥4.14 | CN¥4.96 | CN¥4.64 | CN¥5.40 |
| Shares | |||||
| Basic Shares Outstanding | 128.0M | 130.7M | 130.8M | 129.9M | 127.5M |
| Diluted Shares Outstanding | 128.0M | 130.7M | 130.8M | 129.9M | 127.5M |
| Profitability Metrics | |||||
| EBITDA | — | (137.8M) | 16.4M | (72.7M) | 45.1M |
| D&A | — | 96.3M | 92.1M | 70.3M | 52.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026